News
AstraZeneca has produced some fresh data to back up its blockbuster ambitions for camizestrant, tying the oral SERD to a 56% ...
Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk ...
17d
SurvivorNet on MSNA Better Option For Women With Common Type Of Advanced Breast Cancer: The SERENA-6 Trial Provides HopeSwitching to a new drug combination — camizestrant plus a CDK4/6 inhibitor — sooner may have positive results for advanced breast cancer.
14d
News-Medical.Net on MSNEarly camizestrant therapy keeps advanced breast cancer in checkSwitching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains quality of life in patients with ESR1-mutated, hormone receptor-positive advanced ...
AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting: DESTINY-Breast09, MATTERHORN, and ...
Data presented at ASCO show that swapping in the oral drug camizestrant for an older therapy helped sustain the benefit of initial treatment, potentially opening a novel step in patient care.
Ipatasertib combined with fulvestrant significantly extends progression-free survival in ER-positive, HER2-negative ...
Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) led to a ...
According to AZ, SERENA-6 is also the first pivotal trial to show the value of measuring circulating tumour DNA (ctDNA) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results